David B. Solit, MD, Memorial Sloan Kettering Cancer
Center

One long-standing problem in clinical oncology is the variability of treatment response observed in early stage clinical trials. We performed a genetic and functional analysis of an outlier curative response of a patient with metastatic small cell cancer to combined checkpoint kinase 1 (Chk1) inhibition and DNA-damaging chemotherapy. Novel clinical trial designs optimized to confirm phenotype-to-genotype correlations identified in n-of-1 studies will also be reviewed.

свернуть